<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00616018</url>
  </required_header>
  <id_info>
    <org_study_id>COMIRB #06-1187</org_study_id>
    <secondary_id>COMIRB #06-1187</secondary_id>
    <nct_id>NCT00616018</nct_id>
  </id_info>
  <brief_title>Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days</brief_title>
  <acronym>Non-Drinker</acronym>
  <official_title>Acetaminophen Adduct Formation in Alcohol Abstaining Subjects Administered Therapeutic Doses of Acetaminophen for Ten Consecutive Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kennon Heard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McNeil Consumer &amp; Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Denver Health and Hospital Authority</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acetaminophen is commonly used to treat fever or pain. Your body clears acetaminophen by
      processing it in the liver. During the processing, some of the acetaminophen may bind to
      proteins in the liver. The protein-acetaminophen product is called an &quot;adduct.&quot; After a large
      acetaminophen overdose, the liver has to process a lot of acetaminophen, so large amounts of
      adducts are formed. However, we have found that lower levels may be formed even when people
      take recommended doses. The purpose of this study is to measure the amount of adducts formed
      when healthy people who do not drink alcohol take normal doses of acetaminophen for 10 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Level of Acetaminophen-cysteine (APAP-Cys) Protein Adducts</measure>
    <time_frame>Day 0, 4, 7, 9, 11, and 14.</time_frame>
    <description>Acetaminophen-cysteine (APAP-Cys) protein adduct concentrations were measured at Day 0, 4, 7, 9, 11 and 14. All units are in nmol/mL serum.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALT)</measure>
    <time_frame>Day 0, 4, 7, 9, 11, and 14.</time_frame>
    <description>ALT was measured at Day 0, 4, 7, 9, 11, and 14.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Drug Induced Liver Injury</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>all subjects receive 4 g/day of acetaminophen for 10 consecutive days in this open-label study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetaminophen</intervention_name>
    <description>4 g/day for 10 consecutive days</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Tylenol Extra Strength</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age 21 years or older

          2. provide written informed consent

          3. consume, on average, less than 1 alcoholic beverage daily for the previous 3 months
             and would be considered non-drinkers

        Exclusion Criteria:

          1. History of ingesting more than 4 grams of acetaminophen per day for any of the 4 days
             preceding study enrollment

          2. Currently taking isoniazid

          3. Consumption of any alcoholic beverage during the run-in period

          4. A detectable serum acetaminophen at baseline

          5. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels
             greater than 50 IU/L at the start of the run-in period or at baseline

          6. Platelet count less than 125,000/cc at baseline

          7. Positive pregnancy test at baseline (female participants only)

          8. Currently adheres to a fasting type diet as determined by self report

          9. Currently has anorexia nervosa as determined by self report

         10. Subject appears clinically intoxicated, psychiatrically impaired or unable to give
             informed consent for any reason

         11. Known hypersensitivity to acetaminophen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kennon Heard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Denver Health/Rocky Mountain Poison &amp; Drug Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Denver Health Rocky Mountain Poison and Drug Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2008</study_first_submitted>
  <study_first_submitted_qc>February 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2008</study_first_posted>
  <results_first_submitted>March 3, 2011</results_first_submitted>
  <results_first_submitted_qc>July 10, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 12, 2012</results_first_posted>
  <last_update_submitted>July 10, 2012</last_update_submitted>
  <last_update_submitted_qc>July 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Denver Health and Hospital Authority</investigator_affiliation>
    <investigator_full_name>Kennon Heard</investigator_full_name>
    <investigator_title>Medical Toxicology Fellowship Director</investigator_title>
  </responsible_party>
  <keyword>acetaminophen</keyword>
  <keyword>protein adducts</keyword>
  <keyword>hepatic function</keyword>
  <keyword>drug safety</keyword>
  <keyword>non drinkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chemical and Drug Induced Liver Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study was conducted from August 2007 through January 2008. Healthy volunteers were recruited through flyers posted in community settings.</recruitment_details>
      <pre_assignment_details>Thirty-five subjects were consented for the study. Of these, eight were excluded (six did not meet inclusion criteria and two refused to participate). The 27 eligible subjects were assigned to the treatment arm to receive 4 grams of acetaminophen per day, for 10 consecutive days.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Acetaminophen</title>
          <description>all subjects receive 4 g/day of acetaminophen for 10 consecutive days in this open-label study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acetaminophen</title>
          <description>all subjects receive 4 g/day of acetaminophen for 10 consecutive days in this open-label study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.3" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Level of Acetaminophen-cysteine (APAP-Cys) Protein Adducts</title>
        <description>Acetaminophen-cysteine (APAP-Cys) protein adduct concentrations were measured at Day 0, 4, 7, 9, 11 and 14. All units are in nmol/mL serum.</description>
        <time_frame>Day 0, 4, 7, 9, 11, and 14.</time_frame>
        <population>Analysis is based upon the 24 subjects who completed all study visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Acetaminophen</title>
            <description>all subjects receive 4 g/day of acetaminophen for 10 consecutive days in this open-label study</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Level of Acetaminophen-cysteine (APAP-Cys) Protein Adducts</title>
          <description>Acetaminophen-cysteine (APAP-Cys) protein adduct concentrations were measured at Day 0, 4, 7, 9, 11 and 14. All units are in nmol/mL serum.</description>
          <population>Analysis is based upon the 24 subjects who completed all study visits.</population>
          <units>nmol/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Aminotransferase (ALT)</title>
        <description>ALT was measured at Day 0, 4, 7, 9, 11, and 14.</description>
        <time_frame>Day 0, 4, 7, 9, 11, and 14.</time_frame>
        <population>Analysis is based upon the 24 subjects who completed all study visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Acetaminophen</title>
            <description>acetaminophen treatment group</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase (ALT)</title>
          <description>ALT was measured at Day 0, 4, 7, 9, 11, and 14.</description>
          <population>Analysis is based upon the 24 subjects who completed all study visits.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3" spread="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3" spread="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.8" spread="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.1" spread="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from time of first dose of study medication through followup visits.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Acetaminophen</title>
          <description>all subjects receive 4 g/day of acetaminophen for 10 consecutive days in this open-label study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>migraine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>One limitation is that this study did not include a placebo group. The study was limited to healthy volunteers. The ingestion of each dose and use of other medications was self-reported.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jody Green</name_or_title>
      <organization>Denver Health</organization>
      <phone>303-389-1246</phone>
      <email>jody.green@rmpdc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

